Avoro Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Avoro Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,600,000	Closed	-$60.9M	–	34
2019 Q3	$60.9M	Buy	1,600,000 +1,200,000	+300%	+$47.9M	2.54%	15
2019 Q2	$17.4M	Hold	400,000	–	–	0.6%	26
2019 Q1	$15.2M	Hold	400,000	–	–	0.66%	24
2018 Q4	$17.2M	Sell	400,000 -13,196	-3%	-$616K	1.03%	20
2018 Q3	$20.3M	Sell	413,196 -1,047,414	-72%	-$45.3M	0.93%	22
2018 Q2	$46.8M	Sell	1,460,610 -254,462	-15%	-$8.79M	1.8%	20
2018 Q1	$53.4M	Buy	1,715,072 +866,500	+102%	+$30.9M	2.55%	16
2017 Q4	$38.7M	Sell	848,572 -462,888	-35%	-$18.3M	2.51%	16
2017 Q3	$49.2M	Buy	1,311,460 +845,642	+182%	+$34M	3.82%	9
2017 Q2	$22.2M	Buy	465,818 +55,818	+14%	+$2.59M	2.81%	13
2017 Q1	$18.7M	Buy	+410,000	New	+$17.7M	2.39%	16

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Avoro Capital Advisors's PCRX Position: Q4 2019 in Review

Avoro Capital Advisors sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 1,600,000 shares — an estimated $60.9M sold.

Avoro Capital Advisors first reported a position in PCRX in Q1 2017 and held it in 11 quarters. The position peaked at $60.9M in Q3 2019. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

Avoro Capital Advisors reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
Avoro Capital Advisors sold 1,600,000 Pacira BioSciences shares in Q4 2019, an estimated $60.9M.
Avoro Capital Advisors first reported a position in Pacira BioSciences in Q1 2017 and held it in 11 quarters.
Avoro Capital Advisors's Pacira BioSciences position peaked at $60.9M in Q3 2019.
231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Avoro Capital Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.